Uniqure Nv Stock Today
| QURE Stock | USD 14.20 0.42 3.05% |
PerformanceVery Weak
| Odds Of DistressLow
|
Uniqure NV is trading at 14.20 as of the 17th of March 2025, a 3.05 percent up since the beginning of the trading day. The stock's lowest day price was 13.86. Uniqure NV has less than a 14 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of June 2007 | Category Healthcare | Classification Health Care |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. The company also engages in developing AMT-130, a gene therapy that is in Phase III clinical study for the treatment of Huntingtons disease AMT-060, which is in Phase III clinical trial for the treatment of hemophilia B AMT-210, a product candidate for the treatment of Parkinsons disease AMT-260 for temporal lobe epilepsy AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimers disease and AMT-161 for the treatment of amyotrophic lateral sclerosis. The company has 54.08 M outstanding shares of which 2.44 M shares are at this time shorted by private and institutional investors with about 2.88 trading days to cover. More on Uniqure NV
Moving against Uniqure Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Uniqure Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Matthew CPA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsUniqure NV can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Uniqure NV's financial leverage. It provides some insight into what part of Uniqure NV's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Uniqure NV (QURE) is traded on NASDAQ Exchange in USA. It is located in Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP and employs 209 people. Uniqure NV is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 767.89 M. Uniqure NV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.08 M outstanding shares of which 2.44 M shares are at this time shorted by private and institutional investors with about 2.88 trading days to cover.
Uniqure NV currently holds about 500.52 M in cash with (182.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.71.
Check Uniqure NV Probability Of Bankruptcy
Ownership AllocationUniqure NV shows a total of 54.08 Million outstanding shares. The majority of Uniqure NV outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Uniqure NV to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Uniqure NV. Please pay attention to any change in the institutional holdings of Uniqure NV as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Uniqure Ownership Details
Uniqure Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Integral Health Asset Management, Llc | 2024-12-31 | 1.1 M | |
| Fmr Inc | 2024-12-31 | 966.6 K | |
| Rtw Investments, Llc | 2024-12-31 | 903.6 K | |
| Catalio Capital Management, Lp | 2024-12-31 | 902 K | |
| Two Sigma Investments Llc | 2024-12-31 | 878.9 K | |
| Schroder Investment Management Group | 2024-12-31 | 834.1 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 756.9 K | |
| Boxer Capital Management, Llc | 2024-12-31 | 750 K | |
| Privium Fund Management B.v. | 2024-12-31 | 742.2 K | |
| Ecor1 Capital, Llc | 2024-12-31 | 3.4 M | |
| Vestal Point Capital Lp | 2024-12-31 | 3 M |
Uniqure NV Historical Income Statement
Uniqure Stock Against Markets
Uniqure NV Corporate Management
| Maria Cantor | Chief Officer | Profile | |
| Carla Poulson | Interim Officer | Profile | |
| Alexander Kuta | Ex Affairs | Profile | |
| Ricardo Dolmetsch | Pres RD | Profile | |
| Pierre Caloz | Chief Officer | Profile | |
| Eileen Sawyer | Vice Affairs | Profile | |
| Amin Abujoub | Chief Operations | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Uniqure NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Uniqure Stock refer to our How to Trade Uniqure Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Uniqure NV. If investors know Uniqure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Uniqure NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.18) | Earnings Share (4.92) | Revenue Per Share | Quarterly Revenue Growth (0.22) | Return On Assets |
The market value of Uniqure NV is measured differently than its book value, which is the value of Uniqure that is recorded on the company's balance sheet. Investors also form their own opinion of Uniqure NV's value that differs from its market value or its book value, called intrinsic value, which is Uniqure NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Uniqure NV's market value can be influenced by many factors that don't directly affect Uniqure NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Uniqure NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Uniqure NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Uniqure NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.